肿瘤标志物CA19-9、CA242、CEA和CA125联合检测在胰腺癌诊断中的意义

Significance of combined detection of tumor markers CA19-9, CA242, CEA and CA125 in the diagnosis of pancreatic carcinoma

目的探讨肿瘤标志物CA19-9、CA242、CEA和CA125单项检测和联合检测对胰腺癌患者的临床诊断价值。方法检测48例胰腺癌患者以及48例健康体检者外周血清中四种肿瘤标志物的水平,并对结果进行分析。结果胰腺癌患者血清中CA19-9、CA242、CEA与CA125的含量显著高于正常对照组,两者比较差异有统计学意义(P<0.01)。单项检测时CA19-9、CA242、CEA与CA125的敏感性分别为79.2%、54.2%、50.0%和35.4%,特异性分别为87.5%、89.6%、79.2%和70.8%。联合检测时敏感性为93.8%,特异性为100%。结论CA19-9、CA242、CEA与CA125联合检测敏感性和特异性都明显高于单项检测。联合检测较单项血清标志物检测能提高胰腺癌的诊断率。

Objective To explore the clinical diagnostic value of combined detection of tumor markers CA19-9, CA242, CEA and CA125 of pancreatic carcinoma. Methods Detection of serum tumor markers CA19-9, CA242, CEA and CA125 was carried out in 48 patients with pancreatic carcinoma and 48 healthy volunteers. Results The levels of tumor markers in pancreatic carcinoma group were significantly higher than those in the normal control group （P〈0.01）. The sensitivity of CA19-9, CA242, CEA and CA125 in patients with pancreatic carcinomas was 79.2%, 54.2%, 50.0% and 35.4%, respectively. The specificity of CA19-9, CA242, CEA and CA125 was 87.5%, 89.6%, 79.2% and 70.8%, respectively. The sensitivity and specificity of combined detection were 93.8% and 100%. Conclusion The sensitivity and specificity of combined detection of CA199, CA242, CEA and CA125 are higher than that of the single detection, and can improve the detection rate of pancreatic carcinoma.